158 related articles for article (PubMed ID: 34571002)
1. EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma.
Xu T; Dai J; Tang L; Yang L; Si L; Sheng X; Cui C; Chi Z; Kong Y; Guo J
J Invest Dermatol; 2022 Apr; 142(4):1158-1170.e8. PubMed ID: 34571002
[TBL] [Abstract][Full Text] [Related]
2. Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma.
Emran AA; Fisher DE
J Invest Dermatol; 2022 Apr; 142(4):1004-1006. PubMed ID: 35131084
[TBL] [Abstract][Full Text] [Related]
3. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
[TBL] [Abstract][Full Text] [Related]
4. EZH2 as a mediator of treatment resistance in melanoma.
Tiffen JC; Gallagher SJ; Tseng HY; Filipp FV; Fazekas de St. Groth B; Hersey P
Pigment Cell Melanoma Res; 2016 Sep; 29(5):500-7. PubMed ID: 27063195
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma.
Falahat R; Berglund A; Putney RM; Perez-Villarroel P; Aoyama S; Pilon-Thomas S; Barber GN; Mulé JJ
Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33827917
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic state determines the in vivo efficacy of STING agonist therapy.
Falahat R; Berglund A; Perez-Villarroel P; Putney RM; Hamaidi I; Kim S; Pilon-Thomas S; Barber GN; Mulé JJ
Nat Commun; 2023 Mar; 14(1):1573. PubMed ID: 36949064
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
8. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
[TBL] [Abstract][Full Text] [Related]
9. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
11. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
Sun S; Yu F; Xu D; Zheng H; Li M
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context.
Czapla J; Drzyzga A; Matuszczak S; Cichoń T; Rusin M; Jarosz-Biej M; Pilny E; Smolarczyk R
Front Oncol; 2023; 13():1249524. PubMed ID: 37655095
[TBL] [Abstract][Full Text] [Related]
13. STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.
Wilski NA; Stotesbury C; Del Casale C; Montoya B; Wong E; Sigal LJ; Snyder CM
J Immunol; 2020 Jun; 204(11):2961-2972. PubMed ID: 32284333
[TBL] [Abstract][Full Text] [Related]
14. Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.
Tiffen J; Wilson S; Gallagher SJ; Hersey P; Filipp FV
Neoplasia; 2016 Feb; 18(2):121-32. PubMed ID: 26936398
[TBL] [Abstract][Full Text] [Related]
15. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Hines JB; Kacew AJ; Sweis RF
Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
[TBL] [Abstract][Full Text] [Related]
16. Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation.
Li C; Wang Z; Yao L; Lin X; Jian Y; Li Y; Zhang J; Shao J; Tran PD; Hagman JR; Cao M; Cong Y; Li HY; Goding CR; Xu ZX; Liao X; Miao X; Cui R
Nat Commun; 2024 Mar; 15(1):2163. PubMed ID: 38461299
[TBL] [Abstract][Full Text] [Related]
17. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
[TBL] [Abstract][Full Text] [Related]
18. EZH2 as a Regulator of CD8+ T Cell Fate and Function.
Stairiker CJ; Thomas GD; Salek-Ardakani S
Front Immunol; 2020; 11():593203. PubMed ID: 33117406
[TBL] [Abstract][Full Text] [Related]
19. EZH2-CCF-cGAS Axis Promotes Breast Cancer Metastasis.
Duan D; Shang M; Han Y; Liu J; Liu J; Kong SH; Hou J; Huang B; Lu J; Zhang Y
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163710
[TBL] [Abstract][Full Text] [Related]
20. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
